Kite first to submit CAR-T therapy in Europe – PharmaTimes
|
Kite first to submit CAR–T therapy in Europe
PharmaTimes Kite Pharma has submitted the first CAR–T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL). CAR-T offers a new treatment approach … |
